4:09 PM
 | 
Dec 05, 2017
 |  BC Extra  |  Clinical News

Neuralstem rebounds on additional MDD data

Neuralstem Inc. (NASDAQ:CUR) gained $1.97 (176%) to $3.09 on Tuesday after reporting additional data from a Phase II trial of NSI-189 to treat major depressive disorder.

In July, the company's stock fell 50% to $2.81 after reporting top-line data showing that both doses of NSI-189 missed the trial's primary endpoint of improving Montgomery-Asberg Depression Rating Scale (MADRS) score from baseline to week 12 vs. placebo (see...

Read the full 313 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >